500 patients66,097 observations150 daysLIVE

Patient P-03418

Synthetic patientONX-7 · Day 125 · 55–64 · F · baseline S18Steering view · 3DOpen companion preview
Is the drug working?

Immune response 59 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 39%, immune response 40 today; biology is not blocking the drug.

Is a side effect starting?

Drift detected on day 105 (sleep −0.7 h); nothing reported yet — the window to act is open.

Still taking it?

4 of 4 scheduled doses in the last 60 days are biologically confirmed (100%). Dose signature: resting HR +7 bpm, HRV −9 ms.

last 4 doses · green confirmed · amber logged only · red missed
Plan for this patient
stable, no actionrecommendowner · Companionreview day 132Human Model →
Next action
No action indicated; maintain.
Kept if

Trajectory is stable relative to similar patients; keep the current content.

Daily to-dos in the companion
  • 🍽Keep meals regular; three to four moderate portions spaced through the day
  • 🍽Include a cooked vegetable portion with each main meal
  • Log the daily check-in; one line is enough
  • A 15-minute walk after lunch
  • 💊Take the scheduled dose as agreed with your care team
  • 💊No additional supplements this week
Adherence
84% worsening

Adherence is not the problem.

Changes the plan if

sleep quality falling under 35 while GI rises

LLIFE OS insight
grounded · add an LLM key for prose

P-03418 is on day 125 of ONX-7 (EC-01, baseline S18): response unstable, tolerance favorable, GI improving. Over 14 days response moved +3 and GI -8; discontinuation risk is 11%. The state is between basins, heading towards restoration, after diverging from the model on day 105.

Biology sets the gain: Low butyrate capacity, Low microbial diversity; butyrate capacity 37/100, diversity 2.2. Pushing it down: Low butyrate capacity (-30), Enterococcus faecium 9.962% (LPS load) (-28), 4 keystone species absent (-22.5). Pulling it up: Behavioural Recommendation BR-03 (+15.1), Protein (supports) (+14.2). From the daily log: fat +3.7 GI next day, lactose +3.6 GI next day, protein -3.6 GI next day.

Past actions: BR-03 on day 91 → improved (12%).

No action is indicated now; the trajectory is stable relative to similar patients.

Therapy response
Unstable
Tolerance
Favorable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
11%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (infusion on day 1 of each 14-day cycle)
  1. Day 0 ONX-7 startedBaseline state S18
  2. Day 90 BR-03 recommendedBehavioural Recommendation BR-03
  3. Day 91 Patient acceptedStarted BR-03 in the companion
  4. Day 98 GI symptom burden −12% vs expectedBehavioural Recommendation BR-03
  5. Day 104 Tolerance state changedUnstable → Improving
  6. Day 105 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 105.

Primary contributors, last 14 days
  • GI instability-8
  • Inflammatory activity-6
  • Nutritional resilience+5
  • Treatment adherence-4
  • Toxicity+2

What helped?

  • Behavioural Recommendation BR-03Day 90
    Result: symptom burden −12%
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

Daily trackers

Asset settings

The trackers this program marks as important, last 14 days vs the 14 before.

Energy level
Daily log
5.6/10
stable · -0.0 vs previous 14 d
Stress level
Daily log
3.8/10
improving · -0.5 vs previous 14 d
Pessimism score
Daily log
4.3/10
worsening · +0.3 vs previous 14 d
Sleep quality
Wearable
36.6/100
stable · +0.5 vs previous 14 d
Libido
Daily log
5.2/10
improving · +0.3 vs previous 14 d
HRV
Wearable
34.8 ms
stable · +0.3 vs previous 14 d
Toxicity
Blood
2.1/100
improving · -3.1 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →

Heading towards restoration · 71 from the failing basin, 38 from restoration.

Good elements to keep
  • Behavioural Recommendation BR-03
    intervention · steering +15.1
  • Protein (supports)
    perturbation · steering +14.2
  • Daily walks resumed
    perturbation · steering +3.3
  • Protein
    supporter · GI -3.6 next day
Main detractors to watch
  • Low butyrate capacity
    hidden · steering -30
  • Enterococcus faecium 9.962% (LPS load)
    hidden · steering -28
  • 4 keystone species absent
    hidden · steering -22.5
  • Tissue recycling 46/100
    hidden · steering -14.4
  • Dietary fat load
    detractor · GI +3.7 next day
  • Lactose
    detractor · GI +3.6 next day
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +3.7detractor · 95%
  • Lactose
    +3.6detractor · 95%
  • Protein
    -3.6supporter · 95%
  • Alcohol
    +1.4no signal · 41%
  • Caffeine
    -0.4no signal · 15%
  • Histamine load
    0no signal · 15%

DeepGene damage signature

The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

Damage score · retest day 90
63/100
vs baseline (day 0)
-1
3 improved · 4 worsened
synthetic signature · consistent with this patient's biology
  • 2 opportunists above range: Enterococcus faecium, Clostridioides difficile
  • 4 keystone species absent
  • Shannon 2.63 (expected ≥ 3)
  • 8 resistance genes
  • Tissue recycling index 46
Pathogens / opportunists2/5
from 3
Keystone species4/8
from 3
Diversity2/2
from 1
Metabolic modules1/4
Vitamin synthesis3/7
Oral translocation1/1
Host DNA0/1
from 1
Tissue recycling1/1
Central mechanisms0/2
Virulence factors4/4
from 3
Antibiotic resistance genes8/8
Genetic predisposition1/1
Opportunists above range
Enterococcus faecium 9.962% AR
Clostridioides difficile 1.992% AR
Keystone species absent
Akkermansia muciniphila, Bifidobacterium longum, Butyricicoccus pullicaecorum, Eubacterium rectale
Capacity
Shannon 2.63 · butyrate 578 CPM · SCFA 940
H2S above band
3 vitamins below
Host & mechanisms
tissue recycling 46/100
oral translocation 4.53% AR
8 resistance genes · 4 virulence factors

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production 60
    • MicrobiomeButyrate capacity 37/100
    • MicrobiomeF. prausnitzii depleted
  • Mucosal barrier integrity 40
    • MicrobiomeAkkermansia low → thinner mucus layer
    • WearableSleep 6.0 h, below personal baseline
  • Autonomic recovery 20
    • WearableShort sleep window
  • Inflammatory signalling 15
    • WearableHRV 35 ms, trending down
DNA
Fictional pharmacogenomic panel
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.2 · butyrate capacity 37/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisNormal
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
32 ms
Sleep
6.0 h
Steps
3,384
Resting HR
69 bpm
Daily log: GI score 19, nutritional resilience 66, adherence 84.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Keep meals regular; three to four moderate portions spaced through the day
  • Include a cooked vegetable portion with each main meal
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Log the daily check-in; one line is enough
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • No additional supplements this week
  • Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0316137%S0131
P-0310835%S01BR-03no change60
P-0327033%S01AD-05no change37
P-0325132%S0159
P-0329332%S0130
P-0337831%S0132
P-0324330%S0136
P-0331930%S0158
P-0342030%S0133
P-0312029%S0166
P-0317029%S01ME-01improved31
P-0321229%S0155